Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Myeloid 1CNS 1Breast 1

Conditions

Mesothelioma, Malignant 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × fresolimumab × Thoracic × Clear all
NCT02581787 2024-03-27

SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

Stanford University

Phase 1/2 Completed
28 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01112293 2020-04-10

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
14 enrolled 10 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡